scholarly journals Monomethyl Fumarate (MMF, Bafiertam) for the Treatment of Relapsing Forms of Multiple Sclerosis (MS)

2021 ◽  
Vol 13 (2) ◽  
pp. 207-223
Author(s):  
Amnon A. Berger ◽  
Emily R. Sottosanti ◽  
Ariel Winnick ◽  
Jonathan Izygon ◽  
Kevin Berardino ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Antibody Therapy ◽  
Autoimmune Disorder ◽  
Oral Agents ◽  
Relapsing Remitting ◽  
Recent Addition ◽  
Disease Modifying ◽  
Disease Modifying Agents ◽  
Gait Abnormalities ◽  
Monomethyl Fumarate

Multiple sclerosis (MS) is a prevalent neurologic autoimmune disorder affecting two million people worldwide. Symptoms include gait abnormalities, perception and sensory losses, cranial nerve pathologies, pain, cognitive dysfunction, and emotional aberrancies. Traditional therapy includes corticosteroids for the suppression of relapses and injectable interferons. Recently, several modern therapies—including antibody therapy and oral agents—were approved as disease-modifying agents. Monomethyl fumarate (MMF, Bafiertam) is a recent addition to the arsenal available in the fight against MS and appears to be well-tolerated, safe, and effective. In this paper, we review the evidence available regarding the use of monomethyl fumarate (Bafiertam) in the treatment of relapsing-remitting MS.

scholarly journals New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come

2012 ◽  
Vol 4 ◽  
pp. JCNSD.S6692 ◽  
Author(s):  
J. Nicholas ◽  
B. Morgan-Followell ◽  
D. Pitt ◽  
M.K. Racke ◽  
A. Boster
Keyword(s):  
Multiple Sclerosis ◽  
Safety Data ◽  
Treatment Algorithms ◽  
Disease Modifying Therapies ◽  
Therapeutic Landscape ◽  
Oral Agents ◽  
Relapsing Remitting ◽  
Disease Modifying ◽  
To Come ◽  
Relapsing Remitting Multiple Sclerosis

The therapeutic landscape for multiple sclerosis (MS) is rapidly changing. Currently, there are eight FDA approved disease modifying therapies for MS including: IFN-β-1a (Avonex, Rebif), IFN-β-1b (Betaseron, Extavia), glatiramer acetate (Copaxone), mitoxantrone (Novantrone), natalizumab (Tysabri), and fingolimod (Gilenya). This review will highlight the experience to date and key clinical trials of the newest FDA approved agents, natalizumab and fingolimod. It will also review available efficacy and safety data on several promising therapies under active investigation including four monoclonal antibody therapies: alemtuzumab, daclizumab, ocrelizumab and ofatumumab and three oral agents: BG12, laquinimod, and teriflunomide. To conclude, we will discuss where each of these new therapies may best fit into treatment algorithms.

scholarly journals Latin American algorithm for treatment of relapsing-remitting multiple sclerosis using disease-modifying agents

2012 ◽  
Vol 70 (10) ◽  
pp. 799-806 ◽  
Author(s):  
Alessandro Finkelsztejn ◽  
Alberto Alain Gabbai ◽  
Yara Dadalti Fragoso ◽  
Adriana Carrá ◽  
Miguel Angel Macías-Islas ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Latin America ◽  
Latin American ◽  
North American ◽  
Scientific Evidence ◽  
Relapsing Remitting ◽  
Disease Modifying ◽  
Remitting Multiple Sclerosis ◽  
Disease Modifying Agents ◽  
Relapsing Remitting Multiple Sclerosis

OBJECTIVE: It is estimated that circa 50,000 individuals have relapsing-remitting multiple sclerosis in Latin America. European and North-American algorithms for the treatment of multiple sclerosis do not foresee our regional difficulties and the access of patients to treatment. METHODS: The Latin American Multiple Sclerosis Forum is an independent and supra-institutional group of experts that has assessed the latest scientific evidence regarding efficacy and safety of disease-modifying treatments. Accesses to treatment and pharmacovigilance programs for each of the eight countries represented at the Forum were also analyzed. RESULTS: A specific set of guidelines based upon evidence-based recommendations was designed for Latin America. Future perspectives of multiple sclerosis treatment were also discussed. CONCLUSIONS: The present paper translated an effort from representatives of eight countries discussing a matter that cannot be adapted to our region directly from purely European and North-American guidelines for treatment.

scholarly journals Adherence to Disease-Modifying Agents and Association with Quality of Life Among Patients with Relapsing-Remitting Multiple Sclerosis

2010 ◽  
Vol 12 (2) ◽  
pp. 51-58 ◽  
Author(s):  
Mirela Cerghet ◽  
Elizabeth Dobie ◽  
Jennifer Elston Lafata ◽  
Lonni Schultz ◽  
Stanton Elias ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Multiple Sclerosis ◽  
Estimating Equation ◽  
Cross Sectional ◽  
Relapsing Remitting ◽  
Disease Modifying ◽  
Remitting Multiple Sclerosis ◽  
Disease Modifying Agents ◽  
Relapsing Remitting Multiple Sclerosis

This study was conducted to evaluate the association of adherence to disease-modifying agents (DMAs) and outcomes among multiple sclerosis (MS) patients in a practice setting. The study had a cross-sectional design. A survey was administered to 214 patients with relapsing-remitting multiple sclerosis (RRMS) to measure quality of life, health status, disability, and employment. Measures of health-care costs and adherence to DMAs were constructed using claims data. The relationship between DMA adherence and outcomes was evaluated using generalized estimating equation methods, adjusting for patient sociodemographic characteristics, comorbidities, medication on hand at the time of the survey, insurance status, prescription copay, and duration of disease. A total of 163 patients (76%) responded to the survey, of whom 111 had been dispensed a DMA. Mean adherence in the 12-month period preceding the survey was 78.1%. Patients with higher adherence had better mental health and pain interference scores. Increasing adherence was also associated with a greater likelihood of employment and lower Expanded Disability Status Scale score. These findings illustrate the potential for improved outcomes among RRMS patients who adhere to DMA regimens and highlight the importance of considering medication adherence when evaluating DMA use and outcomes in practice.

Sign in / Sign up

Export Citation Format

Share Document